MYCN Gene Amplification
Maisa Yoshimoto(University of Alberta), Joyce Anderson Duffles Andrade(Associação Paulista de Medicina), Sílvia Regina Caminada de Toledo(Support group for adolescents and children with cancer), Eliana Maria Monteiro Caran(Universidade Federal de São Paulo), Maria Teresa de Seixas Alves(Associação Paulista de Medicina), Maria Lúcia de Martino Lee(Universidade Federal de São Paulo), Simone de Campos Vieira Abib(Support group for adolescents and children with cancer), Sonia Maria Rossi Vianna(Hospital do Servidor Público Estadual)
Cited by 32
Related Papers
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
|British Journal of Cancer|2007|294
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome
|Modern Pathology|2008|278
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma
|JAMA Oncology|2020|251
<i>PTEN</i> genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer
|The Journal of Pathology|2009|210